Literature DB >> 17710428

Psychotropic medication during pregnancy and lactation.

Sharmila J Menon1.   

Abstract

Despite the traditional notion that pregnancy is a time of joy and emotional well being, evidence suggests that it does not protect women against mental illness. Untreated mental illness carries wide-ranging repercussions for mother, child and family that often outweigh those associated with treatment. Clinical management is complex, involving competing risks to mother and offspring; the challenge lies in effectively treating mental illness, whilst minimising exposure of the child to harmful medication. The paucity of robust published evidence on which to base the principles of psychiatric care further compounds the issue. Pregnancy significantly affects plasma drug levels and immature foetal/neonatal physiology renders the child prone to damage from pharmacological agents, all of which cross the placenta/enter breast-milk to varying degrees. Risks include teratogenicity, obstetrical complications, perinatal syndromes, and long-term behavioural problems. Despite evidence that some psychotropic drugs may be safe during pregnancy, knowledge regarding the risks of antenatal exposure to medications remains far from complete. The pregnant or breastfeeding woman requires an individualised risk-benefit analysis with regard to the commencement or continuance of psychotropic medication. If treatment is deemed necessary, monotherapy at the lowest possible dose should be prescribed. More robust safety data is available for older psychotropic drugs, which should be employed in preference to newer agents with unestablished safety profiles. Pregnant/breastfeeding women should also be educated with regard to early detection of signs of drug toxicity in both themselves and their babies. Despite shared responsibility, the ultimate decision with regard to reasonable risk, and what constitutes it, rests with the informed patient. Close psychiatric monitoring and coordinated multidisciplinary care with the obstetrician and paediatrician combine with such informed patient choices to comprise the components of a holistic model of care, targeted at optimizing the complex management of women with psychiatric illness during pregnancy.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710428     DOI: 10.1007/s00404-007-0433-2

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  8 in total

Review 1.  Maintaining fertility in young women with breast cancer.

Authors:  Melissa C Hulvat; Jacqueline S Jeruss
Journal:  Curr Treat Options Oncol       Date:  2009-12

Review 2.  Antipsychotic therapy during early and late pregnancy. A systematic review.

Authors:  Salvatore Gentile
Journal:  Schizophr Bull       Date:  2008-09-11       Impact factor: 9.306

3.  Canadian Network for Mood and Anxiety Treatments (CANMAT) and International Society for Bipolar Disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder.

Authors:  Lakshmi N Yatham; Sidney H Kennedy; Sagar V Parikh; Ayal Schaffer; David J Bond; Benicio N Frey; Verinder Sharma; Benjamin I Goldstein; Soham Rej; Serge Beaulieu; Martin Alda; Glenda MacQueen; Roumen V Milev; Arun Ravindran; Claire O'Donovan; Diane McIntosh; Raymond W Lam; Gustavo Vazquez; Flavio Kapczinski; Roger S McIntyre; Jan Kozicky; Shigenobu Kanba; Beny Lafer; Trisha Suppes; Joseph R Calabrese; Eduard Vieta; Gin Malhi; Robert M Post; Michael Berk
Journal:  Bipolar Disord       Date:  2018-03-14       Impact factor: 6.744

4.  Impact of physician counseling and perception of teratogenic risks: a survey of 96 nonpregnant women with anxiety.

Authors:  Tiffany Behringer; Bruce L Rollman; Bea Herbeck-Belnap; Patricia R Houck; Sati Mazumdar; Eleanor Bimla Schwarz
Journal:  Prim Care Companion CNS Disord       Date:  2011

Review 5.  Treatment considerations for patients with neuropathic pain and other medical comorbidities.

Authors:  Maija L Haanpää; Geoffrey K Gourlay; Joel L Kent; Christine Miaskowski; Srinivasa N Raja; Kenneth E Schmader; Christopher D Wells
Journal:  Mayo Clin Proc       Date:  2010-03       Impact factor: 7.616

Review 6.  Effect of atypical antipsychotics on fetal growth: is the placenta involved?

Authors:  Sandeep Raha; Valerie H Taylor; Alison C Holloway
Journal:  J Pregnancy       Date:  2012-07-11

7.  Avoiding risk at what cost? Putting use of medicines for breastfeeding women into perspective.

Authors:  Lisa H Amir; Kath M Ryan; Susan E Jordan
Journal:  Int Breastfeed J       Date:  2012-10-17       Impact factor: 3.461

8.  Reduction in mortality and teratogenicity following simultaneous administration of folic acid and vitamin E with antiepileptic, antihypertensive and anti-allergic drugs.

Authors:  Shahana Wahid; Rafeeq Alam Khan; Zeeshan Feroz
Journal:  J Pharm Bioallied Sci       Date:  2014-07
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.